drugset
drugset / Trial / NCT06085638

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

NCT06085638 ↗

Phase 1/2 Withdrawn M.D. Anderson Cancer Center Syros Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

To learn if adding venetoclax to the chemotherapy combination of tamibarotene and azacitidine is more effective than tamibarotene and azacitidine alone in treating higher-risk CMM

Timeline

Start
2023-09-14
Primary completion
2023-10-20
Completion
2023-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Tamibarotene Small molecule — Oral
Subject Venetoclax Small molecule — Oral

Indications

chronic myelomonocytic leukemia